Get started
Author

Marı́a del Monte-Millán

Observed names: Del Monte-Millán, M., Del Monte-Millán, Maria, M Del Monte-Millan, M. Del Monte-Millan, M. Del Monte-Millán, M. Monte-Millán, M. del Monte-Millan, M. del Monte-Millán, Maria Del Monte-Millan, Maria Del Monte-Millán, Maria del Monte-Millan, Maria del Monte-Millán, María Del Monte-Millan, María Del Monte-Millán, María del Monte-Millan, María del Monte-Millán, María del Monte‐Millán, Monte Millan, María del
Observed institutions: Universidad Complutense de Madrid, Universitas Gadjah Mada, Instituto de Salud Carlos III, Hospital General Universitario Gregorio Marañón, Yale University, University of Mississippi, Centro de Investigación Biomédica en Red, Centro de Investigación Biomédica en Red de Cáncer, GEICAM – Spanish Breast Cancer Group, Instituto de Investigación Sanitaria Gregorio Marañón, Universitat de Barcelona, University of Bologna
ORCID: 0000-0002-4499-5906
Observed ORCID: 0000-0002-4499-5906
OpenAlex ID: A5077595778
Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib
2011 · Juan Manuel Domínguez, Ana Fuertes, et al. · Journal of Biological Chemistry · 246
PDF
Design, Synthesis, and Biological Evaluation of Dual Binding Site Acetylcholinesterase Inhibitors: New Disease-Modifying Agents for Alzheimer's Disease
2005 · Pilar Muñoz-Ruiz, Laura Rubio, et al. · Journal of Medicinal Chemistry · 220
Glycogen Synthase Kinase-3 (GSK-3) Inhibitory Activity and Structure–Activity Relationship (SAR) Studies of the Manzamine Alkaloids. Potential for Alzheimer’s Disease
2007 · Mark Hamann, Diana Alonso, et al. · Journal of Natural Products · 153
Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts
2016 · Priyanka Sharma, Sara López-Tarruella, et al. · Clinical Cancer Research · 141
PDF
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
2018 · Priyanka Sharma, Sara López-Tarruella, et al. · Clinical Cancer Research · 124
Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification
2018 · Isabel Echavarria, Sara López-Tarruella, et al. · Clinical Cancer Research · 121
PDF
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
2023 · G. Villacampa, N.M. Tung, et al. · Annals of Oncology · 60
PDF
Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series
2019 · A. C. Picornell, I. Echavarria, et al. · BMC Genomics · 57
PDF
Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling
2018 · M. Martín, J. C. de la Torre-Montero, et al. · Breast Cancer Research and Treatment · 41
PDF
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy
2024 · M. Martín, S.R. Stecklein, et al. · Annals of Oncology · 38
PDF
Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial
2016 · Milagros González-Rivera, Miriam Lobo, et al. · Breast Cancer Research and Treatment · 37
Assessment of a Genomic Assay in Patients With ERBB2 -Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab
2023 · Coralia Bueno-Muiño, Isabel Echavarría, et al. · JAMA Oncology · 34
PDF
Outcomes of COVID-19 in Patients With Lung Cancer Treated in a Tertiary Hospital in Madrid
2020 · Antonio Calles, María Inmaculada Aparicio, et al. · Frontiers in Oncology · 34
PDF
Dual Binding Site Acetylcholinesterase Inhibitors: Potential New Disease-Modifying Agents for AD
2006 · María del Monte-Millán, Esther García-Palomero, et al. · Journal of Molecular Neuroscience · 32
Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
2021 · Miguel Martin, Rocio Ramos-Medina, et al. · Scientific Reports · 30
PDF
Technical Challenges for CTC Implementation in Breast Cancer
2021 · Rocío Ramos-Medina, Sara López-Tarruella, et al. · Cancers · 27
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis
2025 · Guillermo Villacampa, Tomás Pascual, et al. · The Lancet Oncology · 26
Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer
2020 · Rocío Núñez-Torres, Miguel Martín, et al. · JAMA Dermatology · 24
Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience
2019 · S. Pérez Ramírez, M. del Monte-Millán, et al. · Clinical & Translational Oncology · 20
Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024 · Miguel Martín, Rachel Yoder, et al. · Clinical Cancer Research · 18
PDF
Concordance of Genomic Variants in Matched Primary Breast Cancer, Metastatic Tumor, and Circulating Tumor DNA: The MIRROR Study
2019 · Fernando Moreno, Javier Gayarre, et al. · JCO Precision Oncology · 15
Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study
2023 · Sara Lopez-Tarruella, María Del Monte-Millán, et al. · Breast Cancer Research and Treatment · 14
PDF
A prospective observational study for a Federated Artificial Intelligence solution for moniToring mental Health status after cancer treatment (FAITH): study protocol
2022 · Raquel Lemos, Sofia Areias-Marques, et al. · BMC Psychiatry · 14
PDF
Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer
2016 · Isabel Echavarria, Mónica Granja, et al. · Breast Cancer Research and Treatment · 12
A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer
2025 · Rita A. Mukhtar, Soumya Gottipati, et al. · npj Breast Cancer · 7
PDF
Works count: 116
Citation count: 1,592
H-index: 19
I10-index: 24
Year
Topic
Type